1. Study of Drugs used to Treat Cardiovascular Disease
in the Hospital Dr Rafael Ángel Calderón Guardiain the Hospital Dr. Rafael Ángel Calderón Guardia
(Costa Rica) in 2011Authors
Alfaro A3; Castro, J1; Hall, V2; Lizano, C2; Morera M1; Pereira, A2; Quesada, G3; Rocha, M2; Rueda, K1; Villalobos, E3.
1 Pharmacy student (intern) at Universtiy of Costa Rica
2Pharmacist at National Drug Information Center (CIMED®). INIFAR. Pharmacy Faculty, University of Costa Rica
3 Pharmacist at Caja Costarricense de Seguro Social
Contact details: victoria.hall@ucr.ac.cr
I.Background
The World Health Organization (WHO) defines drug utilization research (DUR) as a study that aims to analyze the marketing distributionThe World Health Organization (WHO) defines drug utilization research (DUR) as a study that aims to analyze the marketing, distribution,
prescription and use of drugs in a society, with special interest in the resulting medical, social and economic consequences. In Costa Rica,
the primary cause of mortality is cardiovascular disease. Consequently, this study focused on the drugs used to treat three of its related
pathologies.
II.Aims
Analyze consumption of the drugs available during 2011 in the Hospital Dr. Rafael Ángel Calderón Guardia with the Caja Costarricense de
Seguro Social (CCSS) for the treatment of high blood pressure, diabetes mellitus and dyslipidemia.g ( ) g p , y p
III.Methods
_Type of study: Quantitative DUR - consumption
_Method: The Hospital Pharmacy determined which drugs were prescribed most for each disease for the years 2009, 2010 and 2011; the
drugs to be studied for this DUR were selected based on the results. The DDD per 100,000 population was calculated for each medication.
IV.Results
The DDD per 100 000 population for each of the drugs reviewed for 2011 Table No.1 - DDD per 100,000 population in 2011 for theThe DDD per 100,000 population for each of the drugs reviewed for 2011
revealed that the most consumed drug for each pathology was as follows:
irbesartan for high blood pressure, insulin NPH for diabetes mellitus and
lovastatin for dyslipidemia.
In the case of irbesartan 150 mg, despite its status as the only one of the nine
drugs reviewed that cannot be prescribed by a general practice doctor in the
Seguridad Social system, it was the most prescribed antihypertensive drug in
Medication
DDD per 100,000
population
Irbesartan 150mg 117,56
Table No.1 DDD per 100,000 population in 2011 for the
medications used to treat hypertension, diabetes
mellitus and dyslipidemia at the Hospital Dr. Rafael
Ángel Calderón Guardia
g y , p yp g
the hospital during 2011.
V.Conclusions
The study provided real data on consumption of a group of drugs of
importance to the morbi-mortality of the country during a specific period.
Repetition of this study during several years is necessary to determine
patterns of consumption that permit recommendations toward rational use
Irbesartan 150mg 117,56
Enalapril 20mg 89,89
Atenolol 50mg 27
Insulin NPH 31,61
Metformin 500mg 15,93
Glibenclamide
and cost-containment strategies related to these drugs.
.
Glibenclamide
(Glyburide) 5mg 4,38
Lovastatin 20mg 52,1
Gemfibrozil 600mg 9,9
Cholestyramine Resin 4g
(sachets) 0,32
VI.References
1.Andrés Iglesias JC, Formos Pérez JA, Andrés Rodríguez NF. Introducción a la investigación en farmacia
comunitaria. España: Punto Gráfico SL; 2010.
2.Ausejo M. Estudios de utilización de medicamentos, Estrategias de intervención para la mejora de la calidad
fi i i C f i di t d f é ti d l C j C t i d Sy eficiencia en su uso. Conferencia dictada en curso para farmacéuticos de la Caja Costarricense de Seguro
Social. 17-21 de noviembre del 2003. San José, Costa Rica.
3.WHO International Working Group for Drug Statistics Methodology, WHO Collaborating Centre for Drug
Statistics Methodology, WHO Collaborating Centre for Drug Utilization Research and Clinical Pharmacological
Services. Introduction to drug utilization research . Norway; 2003.
4.Página oficial del WHO Collaborating Centre for Drug Statistics Methodology. www.whocc.no/atcddd.
Consultada el 02 de diciembre del 2010.
5.Caja Costarricense de Seguro Social. Departamento de Farmacoterapia. Lista Oficial de Medicamentos.
2010.
Acknowledgements
Special acknowledgement for the pharmacy students (interns), the Pharmacy
Service at the Hospital Dr. Rafael Ángel Calderón Guardia, the Pharmaceutical
Research Institute (INFAR) and the Pharmacy Faculty of University of Costa
Rica, for their support.